NCT04328844 2026-03-30A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersiOncturaPhase 1 Active not recruiting210 enrolled
NCT01655225 2022-04-08A Study of LY3023414 in Participants With Advanced CancerEli Lilly and CompanyPhase 1 Completed156 enrolled